EOS imaging Installs a System in Boston at the #1 US Pediatric Orthopedic Hospital

13 out of the 20 Highest-Ranked Pediatric Orthopedic Centers in the U.S. have adopted EOS

US clinical results presented at the POSNA annual meeting confirm a 50-fold radiation reduction with Micro Dose option

PARIS--()--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that another of the leading U.S. hospitals for pediatric orthopedics has endorsed EOS imaging technology for its superiority in radiation dose reduction and diagnosis information for orthopedic pediatric imaging.

The Boston based, top-ranked hospital in the U.S. for pediatric orthopedics is installing an EOS imaging system, marking the second installation in the city.

Meanwhile, findings from third-ranked Rady Children’s Hospital-San Diego demonstrated a 50-fold dose reduction in radiation exposure for scoliosis patients imaged using EOS Microdose feature. The data were presented by Dr. Peter Newton, chief of the division of Orthopedics & Scoliosis at Rady Children's Hospital-San Diego during the Pediatric Orthopaedic Society of North America (POSNA) Annual Meeting, held in Atlanta Apr 30- May 2.

Marie Meynadier, CEO of EOS imaging, said, “the installation of EOS in the highest ranking pediatric hospital for orthopedics in the US marks the 13th of the top 20 children’s hospitals in the US to adopt EOS low dose 2D/3D imaging. This strong adoption momentum by key institutions, and data such as that presented by Rady Children’s at the POSNA meeting on ultimate dose reduction, are clearly establishing EOS as the gold standard in orthopedic pediatric imaging.”

The EOS® system provides full-body stereo-radiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans, as well as related software solutions.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 1st half of 2015, on July 20, 2015 (after market).

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 47 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

Contacts

Anne Renevot, +33 (0)1 55 25 61 24
CFO
investors@eos-imaging.com
or
NewCap
Antoine Denry/ Pierre Laurent, +33 (0)1 44 71 94 91
Financial communication and investor relations
eosimaging@newcap.fr
or
The Ruth Group (US)
Calvin Allen, 646-536-7002
Press relations
callen@theruthgroup.com

Contacts

Anne Renevot, +33 (0)1 55 25 61 24
CFO
investors@eos-imaging.com
or
NewCap
Antoine Denry/ Pierre Laurent, +33 (0)1 44 71 94 91
Financial communication and investor relations
eosimaging@newcap.fr
or
The Ruth Group (US)
Calvin Allen, 646-536-7002
Press relations
callen@theruthgroup.com